'''Ifoxetine''' ('''CGP-15,210-G''') is a [[selective serotonin reuptake inhibitor]] (SSRI) which was investigated as an [[antidepressant]] in the 1980s but was never marketed.<ref name="pmid3045107">{{cite journal |vauthors=Burrows GD, McIntyre IM, Judd FK, Norman TR | title = Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness | journal = The Journal of Clinical Psychiatry | volume = 49 Suppl | issue = | pages = 18–22 |date=August 1988 | pmid = 3045107 | doi = | url = }}</ref><ref name="pmid2877890">{{cite journal  |vauthors=Waldmeier PC, Maître L, Baumann PA, etal | title = Ifoxetine, a compound with atypical effects on serotonin uptake | journal = European Journal of Pharmacology | volume = 130 | issue = 1-2 | pages = 1–10 |date=October 1986 | pmid = 2877890 | doi = 10.1016/0014-2999(86)90177-9| url = http://linkinghub.elsevier.com/retrieve/pii/0014-2999(86)90177-9}}</ref><ref name="pmid3320185">{{cite journal  |vauthors=Delini-Stula A, Fischbach R, Gauthier JM, etal | title = First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs | journal = International Clinical Psychopharmacology | volume = 2 | issue = 3 | pages = 201–15 |date=July 1987 | pmid = 3320185 | doi = 10.1097/00004850-198707000-00003| url = }}</ref> Ifoxetine [[binding selectivity|selectively]] blocks the [[reuptake]] of [[serotonin]] in the [[brain]] supposedly without affecting it in the [[wikt:periphery|periphery]].<ref name="pmid3320185"/> Supporting this claim, ifoxetine was found to be efficacious in [[clinical trial]]s and was very well tolerated, producing almost no [[Human body|physical]] [[side effect]]s or other complaints of significant concern.<ref name="pmid3320185"/>
